Genentech, Syndax test atezolizumab/entinostat combo in triple-negative breast cancer
Executive Summary
Syndax Pharmaceuticals Inc. agreed to test a combination of its histone deacetylase inhibitor entinostat with Genentech Inc.'s PD-L1 antagonist antibody atezolizumab (MPDL3280A).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice